Congress trades

Bio-Rad Laboratories, Inc. (BIO)

Medical Devices, listed on NYSE.

22 Congress tradeslast filed Dec 6, 2023

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Nov 4, 2026

Bio-Rad Laboratories beat by 18.8% on adjusted EPS.

$2.65 a share against a $2.23 consensus. Revenue $656M against $650M, in line.

EPS

Reported$2.65
Consensus$2.23

Revenue

Reported$656M
Consensus$650M

Beat 3Miss 3

Next report Feb 11, 2027. Consensus $2.83 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

402

institutions reported Bio-Rad Laboratories shares in 13F filings for Jun 30, 2026. First Eagle Investment Management, LLC held the largest stake, $765.2M.

The largest holders

First Eagle Investment Management, LLC$765.2M
BlackRock, Inc.$498.8M
Dimensional Fund Advisors LP$277.3M
Every holder
Companyfrom the company's filings and listing, as of Nov 13, 2026

About Bio-Rad Laboratories, Inc.

Exchange
NYSE
Sector
Healthcare
Industry
Medical - Devices
Chief executive
Norman D. Schwartz
Employees
7,450
Listed since
Feb 27, 1980
Market value
$10.0B
Price to earnings (12 mo)
9.7
Net income per share, as reported (12 mo)
$38.20
Dividend yield
-

www.bio-rad.com

Earnings6 reported quarters · next on Feb 11, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 4, 2026$2.65$2.23$656.4M$649.9MEPS beatRevenue in line
Q2 FY2026reported Aug 4, 2026$2.62$1.75$651.0M$624.0MEPS beatRevenue beat
Q1 FY2026reported Apr 30, 2026$1.89$1.97$592.1M$589.9MEPS missRevenue in line
Q4 FY2025reported Feb 12, 2026$2.51$2.57$693.2M$688.8MEPS missRevenue in line
Q3 FY2025reported Oct 29, 2025$2.26$2.30$653.0M$694.6MEPS missRevenue miss
Q2 FY2025reported Jul 31, 2025$2.61$1.93$651.6M$633.8MEPS beatRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on BIO yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on BIO, newest first
FirmRatingTargetActionDate
RBC CapitalOutperform$390Raised from $370
Wells FargoEqual Weightrated Aug 5, 2026$310Raised from $290
UBSNot stated$335Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice. A rating with its own date under it is the firm's latest from the past 120 days, where the note stated none.

1 other firm rated BIO in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 13, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Mar 25, 2026

Executive pay

Norman Schwartz’s pay as CEO came to $8.0M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
Norman SchwartzChief Executive Officer and Chairman$1.1M$4.9M$2.0M$8.0M
Jonathan P. DiVincenzoPresident and Chief Operating Officer$673K$2.0M$984K$3.7M
Roop K. LakkarajuExecutive Vice President, Chief Financial Officer$629K$1.6M$743K$3.0M
Rajat MehtaExecutive Vice President, Global Commercial Operations$220K$2.2M$301K$2.7M
James BarryExecutive Vice President, President, Life Science Group$537K$1.2M$860K$2.6M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr% of shares out
First Eagle Investment Management, LLC$765.2M2,606,219+0.1%9.74%
BlackRock, Inc.$498.8M1,698,929+1.1%6.35%
Dimensional Fund Advisors LP$277.3M944,548-13.3%3.53%
Vanguard Capital Management LLC$242.8M826,972-0.5%3.09%
Ariel Investments, LLC$239.8M816,751+3.9%3.05%
Vanguard Portfolio Management LLC$239.6M816,198-1.6%3.05%
Earnest Partners LLC$170.5M580,752-1.4%2.17%
State Street Corp$167.9M571,762+2.2%2.12%
Bank of America Corp$144.0M490,412+10.2%1.83%
Capital World Investors$135.8M462,457+2.8%1.73%
Capital Research Global Investors$130.2M443,483+15.0%1.66%
UBS Am, A Distinct Business Unit of Ubs Asset Management Americas LLC$123.0M418,884-1.7%1.57%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

STOCK Act20 disclosures of 22 on record · median 31d of the 45 allowed

Congress trades in BIO

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Ro KhannaStockSale$1,001 - $15,000+28.7% since the saleEstimated exit price $287.88, close on Fri Nov 3, 2023Current price $370.48, close on Thu Nov 12Nov 3, 2023Dec 6, 202333d
Ro KhannaStockPurchase$1,001 - $15,000+5.4% since the tradeEstimated entry price $351.55, close on Mon Oct 2, 2023Current price $370.48, close on Thu Nov 12Oct 2, 2023Nov 8, 202337d
Ro KhannaStockSale$15,001 - $50,000+27.1% since the saleEstimated exit price $291.53, close on Thu Oct 26, 2023Current price $370.48, close on Thu Nov 12Oct 26, 2023Nov 8, 202313d
Lois FrankelStockSale$1,001 - $15,000+3.5% since the saleEstimated exit price $357.91, close on Fri Sep 8, 2023Current price $370.48, close on Thu Nov 12Sep 8, 2023Oct 10, 202332d
Lois FrankelStockPurchase$1,001 - $15,000+1.7% since the tradeEstimated entry price $364.38, close on Wed Jun 28, 2023Current price $370.48, close on Thu Nov 12Jun 28, 2023Jul 28, 202330d
Lois FrankelStockPurchase$1,001 - $15,000-1.3% since the tradeEstimated entry price $375.24, close on Thu Jun 29, 2023Current price $370.48, close on Thu Nov 12Jun 29, 2023Jul 28, 202329d
Ro KhannaStockSale$1,001 - $15,000-1.3% since the saleEstimated exit price $375.24, close on Thu Jun 29, 2023Current price $370.48, close on Thu Nov 12Jun 29, 2023Jul 11, 202312d
Susie LeeJointStockSale$1,001 - $15,000-10.7% since the saleEstimated exit price $414.71, close on Wed Nov 30, 2022Current price $370.48, close on Thu Nov 12Nov 30, 2022Dec 29, 202229d
Ro KhannaStockPurchase$1,001 - $15,000+1.5% since the tradeEstimated entry price $365.15, close on Thu Nov 3, 2022Current price $370.48, close on Thu Nov 12Nov 3, 2022Dec 6, 202233d
Ro KhannaStockSale$1,001 - $15,000-20.1% since the saleEstimated exit price $463.67, close on Fri Jun 17, 2022Current price $370.48, close on Thu Nov 12Jun 17, 2022Jul 7, 202220d
Ro KhannaStockPurchase$1,001 - $15,000-24.4% since the tradeEstimated entry price $490.17, close on Tue May 10, 2022Current price $370.48, close on Thu Nov 12May 10, 2022Jun 10, 202231d
Tommy TubervilleJointStockSale (Full)$1,001 - $15,000-36.1% since the saleEstimated exit price $580.23, close on Wed Mar 30, 2022Current price $370.48, close on Thu Nov 12Mar 30, 2022Apr 8, 20229d
Ro KhannaStockSale$1,001 - $15,000-49.3% since the saleEstimated exit price $731.44, close on Thu Oct 7, 2021Current price $370.48, close on Thu Nov 12Oct 7, 2021Nov 9, 202133d
Tommy TubervilleJointStockPurchase$1,001 - $15,000-35.0% since the tradeEstimated entry price $570.04, close on Mon Mar 29, 2021Current price $370.48, close on Thu Nov 12Mar 29, 2021Jul 23, 2021116d
Susie LeeJointStockSale$1,001 - $15,000-36.6% since the saleEstimated exit price $584.13, close on Tue Jan 5, 2021Current price $370.48, close on Thu Nov 12Jan 5, 2021Feb 10, 202136d
Susie LeeJointStockSale$1,001 - $15,000-27.5% since the saleEstimated exit price $510.68, close on Fri Oct 2, 2020Current price $370.48, close on Thu Nov 12Oct 2, 2020Dec 8, 202067d
Susie LeeJointStockSale$1,001 - $15,0000.0% since the saleEstimated exit price $370.37, close on Tue Apr 7, 2020Current price $370.48, close on Thu Nov 12Apr 7, 2020Jun 15, 202069d
Susie LeeJointStockSale$1,001 - $15,000-21.3% since the saleEstimated exit price $470.72, close on Wed May 27, 2020Current price $370.48, close on Thu Nov 12May 27, 2020Jun 15, 202019d
Susie LeeJointStockSale$1,001 - $15,000+0.6% since the saleEstimated exit price $368.35, close on Fri Dec 27, 2019Current price $370.48, close on Thu Nov 12Dec 27, 2019Jan 16, 202020d
Susie LeeJointStockPurchase$1,001 - $15,000+22.9% since the tradeEstimated entry price $301.47, close on Tue Jun 25, 2019Current price $370.48, close on Thu Nov 12Jun 25, 2019Jul 18, 201923d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in BIO filterable by party, chamber, type and account.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 13, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on BIO show and how current they are.

Which members of Congress have traded BIO?

Ro Khanna, Lois Frankel, Susie Lee and Tommy Tuberville disclosed BIO transactions in the filings shown here.

How quickly are BIO trades disclosed?

Congressional disclosures took a median of 31 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track